Efficacy of 1064-nm picosecond laser in the treatment of lichen planus pigmentosus: a split-face randomized controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20250311004

Enrollment

Registered

2025-03-11

Start date

2022-12-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Efficacy and safety of 1064-nm picosecond laser treatment for patients with lichen planus pigmentosus (LPP) Lichen planus pigmentosus, Hyperpigmentation, Pigmentation disorders, Laser therapy, Picosecond laser

Interventions

1064-nm picosecond (EnlightenTM System

Cutera Inc.) for 4 sessions at 4-week intervals using the following parameters: spot size 10 mm, fluence 0.4-0.6 J/cm2, frequency 10 Hz, and 2 to 3 passes. All participants continued their existing to

Experimental Device,No Intervention Other

Picosecond laser,No laser treatment (continued existing medications)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.) diagnosed with lichen planus pigmentosus (LPP) confirmed by histopathology, 2.) having bilateral and symmetrical lesions on the face and/or neck, 3.) clinically stable LPP, defined as no new lesions or increase in pigmentation severity, for at least 6 months before study enrollment, and 4.) eligible to follow-up

Exclusion criteria

Exclusion criteria: Exclusion criteria included 1.) co-occurring skin infection, active inflammation, acne vulgaris or open wounds at the treatment site, 2.) history of immunodeficiency, skin cancer, coagulopathy, or recurrent herpes infection, 3.) pregnancy or breastfeeding at the time of enrollment, and 4.) history of laser treatment within 6 months before the study.

Design outcomes

Primary

Measure	Time frame
Improvement in pigmentation severity 0, 1, 2, 3, 4, 6, 9 months Modified dermal pigmentation area and severity index,Improvement in pigmentation severity 0, 1, 2, 3, 4, 6, 9 months Melanin index ,Improvement in pigmentation severity 4 and 9 months Physician global assessment	—

Secondary

Measure	Time frame
Participant satisfaction 4 and 9 months Visual analogue scale	—

Countries

Thailand

Contacts

Public ContactSuthinee Rutnin

Faculty of Medicine, Ramathibodi hospital

skin1465@hotmail.com6622011211

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026